The Forum
The 2022 Virtual World Medical Innovation Forum will focus on the growing impact of gene and cell therapy.
May 2–4, 2022
Gene and cell therapy holds immense potential to advance the quality of patient care, reduce cost, and improve outcomes. Systemic complexity, however, can hinder the translation of breakthroughs to clinical care.
Our collective mission: finding solutions to the medical, operational, and economic challenges confronting GCT-driven care to ensure that patients, providers, and healthcare organizations benefit as soon as possible.
Who Attends
Pharma
Provider
Venture Capital
Medical Device
Investors
Industry Leaders
Engage with peers from across the GCT and machine learning ecosystem. Meet other executives, decision-makers, and business leaders from health care, pharma, medical devices, and biotech.
Clinicians and Investigators
The one event where physician and clinical leaders connect with peers across the medical landscape. Attend plenary panels, networking events, and fireside chats to capture insight into how GCT and other technology is enhancing the care continuum.
Government Leaders
Join leaders from across the spectrum of government roles. Learn about the priorities of officials who are leading government agencies.
Payers
Connect with the executives who are determining how gene and cell therapy will be reimbursed.
Attendees by Industry
0%
Life Sciences and Biotech
0%
Healthcare
0%
Gene and Cell Therapy
0%
Clinician, Investigator, Hospital Staff
0%
Venture and Investment
0%
Non-Profit, Government, Media
2021 GCT White Paper
With a handful of approvals and a triple digit pipeline, gene and cell therapies (GCT) are on the cusp of ushering in a transformation in therapeutics reminiscent to where we were with antibodies 25 years ago.
This summary is to highlight key issues and opportunities brought up by GCT leaders.
The Difference
Why You Need to Be a Part
Past Forums
The Forum has hosted many top-tier speakers since its inception. See the past keynoters, as well as access to videos of the panels.
2021 Steering Committee
Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS (2021 Co-Chair)
Susan Slaugenhaupt, PhD, Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute; Professor, Neurology, HMS (2021 Co-Chair)
Ravi Thadhani, MD, CAO, Mass General Brigham; Professor, Medicine and Faculty Dean, HMS (2021 Co-Chair)
Luk Vandenberghe, PhD, Grousbeck Family Chair, Gene Therapy, MEE; Associate Professor, Ophthalmology, HMS (2021 Co-Chair)
Xandra Breakefield, PhD, Geneticist, MGH; Professor, Neurology, HMS
Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet, Professor of Neurosurgery, HMS
Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor, Neurology, HMS
Meredith Fisher, PhD, Partner, Mass General Brigham Innovation Fund
Jean-Francois Formela, MD, Partner, Atlas Venture
Pat Fortune, PhD, VP, Market Sectors, Mass General Brigham Innovation
Anna Greka, MD, PhD, Medicine, BWH; Associate Professor, Medicine, HMS
Reid Huber, PhD, Partner, Third Rock Ventures
Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor, Neurology and Neuroscience, HMS
J. Keith Joung, MD, PhD, RRobert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; Professor of Pathology, HMS
Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences
Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS
Dave Lennon, PhD, President, Novartis Gene Therapies
John Lepore, MD, SVP, Head of Research, GlaxoSmithKline
Marcela Maus, MD, PhD, Director, Cellular Immunotherapy, Cancer Center, MGH; Associate Professor of Medicine, HMS
Marie McDonnell, MD, Chief, Diabetes Section and Director, Diabetes Program, BWH; Lecturer on Medicine, HMS
Patricia Musolino, MD, PhD, Co-Director Pediatric Stroke and Cerebrovascular Program, MGH; Assistant Professor of Neurology, HMS
Chandra Ramanathan, PhD, Global Head, Pharma R&D Open Innovation, Bayer
Alfred Sandrock, MD, PhD, EVP, R&D and CMO, Biogen
Bastiano Sanna, PhD, EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals
Christine Seidman, MD, Director, Cardiovascular Genetics Center, BWH; Smith Professor of Medicine & Genetics, HMS
